,address1,address2,city,country,phone,fax,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,returnOnAssets,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,Jerusalem BioPark Building,2nd floor Hadassah Ein Kerem Campus,Jerusalem,Israel,972 8 930 2529,972 8 930 2531,https://www.biondvax.com,Biotechnology,Healthcare,"BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.",33,"{'maxAge': 1, 'name': 'Mr. Amir  Reichman M.B.A., M.Sc.', 'age': 46, 'title': 'CEO & Director', 'yearBorn': 1976, 'fiscalYear': 2022, 'totalPay': 562497, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.35,1.32,1.31,1.36,1.35,1.32,1.31,1.36,0.0,2.366182,-0.53333336,22668,22668,40104,120829,120829,0.0,0.0,1800,800,4966625,0.95,11.8,1.345086,2.1568124,0.0,0.0,USD,21940726,0.0,2720488,3651930,4883,4832,1689292800,1692057600,0.0013,0.20017,0.10687,0.32,0.0015,-1.957,1672444800,1703980800,1688083200,-7615000,-2.35,-2.55,-2.11,NCM,EQUITY,BVXV,BVXV,BiondVax Pharmaceuticals Ltd.,BiondVax Pharmaceuticals Ltd.,1431437400,America/New_York,EDT,-14400000,1.36,70.0,8.0,39.0,39.0,none,2,7506000,2.065,-10396000,24613000,3.976,4.115,-0.30893,-9544073,-8430000,0.0,0.0,0.0,USD,
1,Jerusalem BioPark Building,2nd floor Hadassah Ein Kerem Campus,Jerusalem,Israel,972 8 930 2529,972 8 930 2531,https://www.biondvax.com,Biotechnology,Healthcare,"BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.",33,"{'maxAge': 1, 'name': 'Mr. Elad  Mark B.Sc., Eng., M.B.A.', 'age': 40, 'title': 'Chief Operating Officer', 'yearBorn': 1982, 'fiscalYear': 2022, 'totalPay': 277016, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.35,1.32,1.31,1.36,1.35,1.32,1.31,1.36,0.0,2.366182,-0.53333336,22668,22668,40104,120829,120829,0.0,0.0,1800,800,4966625,0.95,11.8,1.345086,2.1568124,0.0,0.0,USD,21940726,0.0,2720488,3651930,4883,4832,1689292800,1692057600,0.0013,0.20017,0.10687,0.32,0.0015,-1.957,1672444800,1703980800,1688083200,-7615000,-2.35,-2.55,-2.11,NCM,EQUITY,BVXV,BVXV,BiondVax Pharmaceuticals Ltd.,BiondVax Pharmaceuticals Ltd.,1431437400,America/New_York,EDT,-14400000,1.36,70.0,8.0,39.0,39.0,none,2,7506000,2.065,-10396000,24613000,3.976,4.115,-0.30893,-9544073,-8430000,0.0,0.0,0.0,USD,
2,Jerusalem BioPark Building,2nd floor Hadassah Ein Kerem Campus,Jerusalem,Israel,972 8 930 2529,972 8 930 2531,https://www.biondvax.com,Biotechnology,Healthcare,"BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.",33,"{'maxAge': 1, 'name': 'Dr. Tamar  Ben-Yedidia Ph.D.', 'age': 58, 'title': 'Chief Science Officer', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 314924, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.35,1.32,1.31,1.36,1.35,1.32,1.31,1.36,0.0,2.366182,-0.53333336,22668,22668,40104,120829,120829,0.0,0.0,1800,800,4966625,0.95,11.8,1.345086,2.1568124,0.0,0.0,USD,21940726,0.0,2720488,3651930,4883,4832,1689292800,1692057600,0.0013,0.20017,0.10687,0.32,0.0015,-1.957,1672444800,1703980800,1688083200,-7615000,-2.35,-2.55,-2.11,NCM,EQUITY,BVXV,BVXV,BiondVax Pharmaceuticals Ltd.,BiondVax Pharmaceuticals Ltd.,1431437400,America/New_York,EDT,-14400000,1.36,70.0,8.0,39.0,39.0,none,2,7506000,2.065,-10396000,24613000,3.976,4.115,-0.30893,-9544073,-8430000,0.0,0.0,0.0,USD,
3,Jerusalem BioPark Building,2nd floor Hadassah Ein Kerem Campus,Jerusalem,Israel,972 8 930 2529,972 8 930 2531,https://www.biondvax.com,Biotechnology,Healthcare,"BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.",33,"{'maxAge': 1, 'name': 'Mr. Uri  Ben-Or CPA, CPA, M.B.A., MBA', 'age': 52, 'title': 'Chief Financial Officer', 'yearBorn': 1970, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.35,1.32,1.31,1.36,1.35,1.32,1.31,1.36,0.0,2.366182,-0.53333336,22668,22668,40104,120829,120829,0.0,0.0,1800,800,4966625,0.95,11.8,1.345086,2.1568124,0.0,0.0,USD,21940726,0.0,2720488,3651930,4883,4832,1689292800,1692057600,0.0013,0.20017,0.10687,0.32,0.0015,-1.957,1672444800,1703980800,1688083200,-7615000,-2.35,-2.55,-2.11,NCM,EQUITY,BVXV,BVXV,BiondVax Pharmaceuticals Ltd.,BiondVax Pharmaceuticals Ltd.,1431437400,America/New_York,EDT,-14400000,1.36,70.0,8.0,39.0,39.0,none,2,7506000,2.065,-10396000,24613000,3.976,4.115,-0.30893,-9544073,-8430000,0.0,0.0,0.0,USD,
4,Jerusalem BioPark Building,2nd floor Hadassah Ein Kerem Campus,Jerusalem,Israel,972 8 930 2529,972 8 930 2531,https://www.biondvax.com,Biotechnology,Healthcare,"BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.",33,"{'maxAge': 1, 'name': 'Mr. Joshua E. Phillipson B.Sc., M.B.A.', 'title': 'Director of Communications & Investor Relations', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.35,1.32,1.31,1.36,1.35,1.32,1.31,1.36,0.0,2.366182,-0.53333336,22668,22668,40104,120829,120829,0.0,0.0,1800,800,4966625,0.95,11.8,1.345086,2.1568124,0.0,0.0,USD,21940726,0.0,2720488,3651930,4883,4832,1689292800,1692057600,0.0013,0.20017,0.10687,0.32,0.0015,-1.957,1672444800,1703980800,1688083200,-7615000,-2.35,-2.55,-2.11,NCM,EQUITY,BVXV,BVXV,BiondVax Pharmaceuticals Ltd.,BiondVax Pharmaceuticals Ltd.,1431437400,America/New_York,EDT,-14400000,1.36,70.0,8.0,39.0,39.0,none,2,7506000,2.065,-10396000,24613000,3.976,4.115,-0.30893,-9544073,-8430000,0.0,0.0,0.0,USD,
5,Jerusalem BioPark Building,2nd floor Hadassah Ein Kerem Campus,Jerusalem,Israel,972 8 930 2529,972 8 930 2531,https://www.biondvax.com,Biotechnology,Healthcare,"BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.",33,"{'maxAge': 1, 'name': 'Ms. Moran Ahdout Fruchter L.L.B.', 'title': 'Chief of Staff', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.35,1.32,1.31,1.36,1.35,1.32,1.31,1.36,0.0,2.366182,-0.53333336,22668,22668,40104,120829,120829,0.0,0.0,1800,800,4966625,0.95,11.8,1.345086,2.1568124,0.0,0.0,USD,21940726,0.0,2720488,3651930,4883,4832,1689292800,1692057600,0.0013,0.20017,0.10687,0.32,0.0015,-1.957,1672444800,1703980800,1688083200,-7615000,-2.35,-2.55,-2.11,NCM,EQUITY,BVXV,BVXV,BiondVax Pharmaceuticals Ltd.,BiondVax Pharmaceuticals Ltd.,1431437400,America/New_York,EDT,-14400000,1.36,70.0,8.0,39.0,39.0,none,2,7506000,2.065,-10396000,24613000,3.976,4.115,-0.30893,-9544073,-8430000,0.0,0.0,0.0,USD,
6,Jerusalem BioPark Building,2nd floor Hadassah Ein Kerem Campus,Jerusalem,Israel,972 8 930 2529,972 8 930 2531,https://www.biondvax.com,Biotechnology,Healthcare,"BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.",33,"{'maxAge': 1, 'name': 'Ms. Dalit Weinstein Fischer', 'title': 'VP and Head of Technical R&D', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.35,1.32,1.31,1.36,1.35,1.32,1.31,1.36,0.0,2.366182,-0.53333336,22668,22668,40104,120829,120829,0.0,0.0,1800,800,4966625,0.95,11.8,1.345086,2.1568124,0.0,0.0,USD,21940726,0.0,2720488,3651930,4883,4832,1689292800,1692057600,0.0013,0.20017,0.10687,0.32,0.0015,-1.957,1672444800,1703980800,1688083200,-7615000,-2.35,-2.55,-2.11,NCM,EQUITY,BVXV,BVXV,BiondVax Pharmaceuticals Ltd.,BiondVax Pharmaceuticals Ltd.,1431437400,America/New_York,EDT,-14400000,1.36,70.0,8.0,39.0,39.0,none,2,7506000,2.065,-10396000,24613000,3.976,4.115,-0.30893,-9544073,-8430000,0.0,0.0,0.0,USD,
